Kala Bio Inc is a biopharmaceutical company dedicated to developing innovative therapies for patients suffering from serious eye diseases. The company focuses on creating treatments that address unmet medical needs, particularly in areas where current options are limited or inadequate. Their research and development efforts are aimed at advancing novel drug delivery systems and formulations that enhance the effectiveness and safety of ophthalmic treatments. Through their commitment to scientific excellence and patient-centric solutions, Kala Bio strives to improve the quality of life for those affected by debilitating vision disorders. Read More
U.S. stocks traded mixed midway through trading, with the Dow Jones falling more than 50 points on Monday. The Dow traded down 0.12% to 46,190.92 while the NASDAQ rose 0.40% to 22,574.89. The S&P 500 also rose, gaining, 0.13% to 6,652.27.
Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands at $5.5 million. Zura Bio (NASDAQ: ZURA) stock moved upwards by 42.94% to $3.44. The company's market cap stands at $156.6 million.
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 150 points on Monday. Following the market opening Monday, the Dow traded up 0.19% to 46,333.68 while the NASDAQ rose 0.67% to 22,635.76. The S&P 500 also rose, gaining, 0.42% to 6,671.51.
The firm stated that its KPI-012 failed in a mid-stage clinical trial and announced that it intends to preserve cash, including by laying off some of its workforce and deploying other cost-saving measures.
ARLINGTON, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the H.C. Wainwright 27th Annual Global Investment Conference being held in New York, NY on Wednesday, September 10, 2025 at 2:00 p.m. ET. Management will be available for one-on-one meetings on Wednesday, September 10, 2025.
-- Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data expected at the end of September 2025 --
ARLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference being held virtually on Wednesday, August 13, 2025. A pre-recorded presentation will be made available beginning on Wednesday, August 13, 2025 at 7:00 a.m. ET. KALA management will also participate in a panel discussion titled “Novel Treatments for Front-of-the-Eye Indications” on Wednesday, August 13, 2025 at 1:00 p.m. ET. Management will be available for virtual one-on-one meetings throughout the conference.
ARLINGTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that the Company will host a webcast event with Key Opinion Leaders (KOLs) to discuss the potential of KPI-012 for the treatment of persistent corneal epithelial defect (PCED). The event will take place on Wednesday, July 16, 2025, at 4:00 p.m. ET.
ARLINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the Jefferies Global Healthcare Conference being held in New York, NY on Thursday, June 5, 2025 at 1:25 p.m. ET. Management will also be available for one-on-one meetings on Thursday, June 5, 2025.
-- Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data anticipated in 3Q 2025 --
ARLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the TD Cowen 45th Annual Health Care Conference being held in Boston, MA on Wednesday, March 5, 2025 at 11:50 a.m. ET. Management will also be available for one-on-one meetings on Wednesday, March 5, 2025.
